A first‐in‐human study of the anti‐inflammatory profibrinolytic TMS‐007, an SMTP family triprenyl phenol
British Journal of Clinical Pharmacology · 2023
DOI: 10.1111/bcp.15651 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2023. Verfasst von Takashi Moritoyo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Support Center, University of Tokyo Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Fibrinolysin, Antifibrinolytic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Science and Technology Agency.
Abstract (Originalsprache)
Aims
TMS‐007, an SMTP family member, modulates plasminogen conformation and enhances plasminogen‐fibrin binding, leading to promotion of endogenous fibrinolysis. Its anti‐inflammatory action, mediated by soluble epoxide hydrolase inhibition, may contribute to its efficacy. Evidence suggests that TMS‐007 can effectively treat experimental thrombotic and embolic strokes with a wide time window, while reducing haemorrhagic transformation. We aim to evaluate the safety, pharmacokinetics and pharmacodynamics of TMS‐007 in healthy volunteers.
Methods
This was a randomized, placebo‐controlled, double blind, dose‐escalation study, administered as a single intravenous infusion of TMS‐007 in cohorts of healthy male Japanese subjects. Six cohorts were planned, but only five were completed. In each cohort ( n = 8), individuals were randomized to receive one of five doses of TMS‐007 (3, 15, 60, 180 or 360 mg; n = 6) or placebo ( n = 2).
Results
TMS‐007 was generally well tolerated, and no serious adverse events were attributed to the drug. A linear dose‐dependency was observed for plasma TMS‐007 levels. No symptoms of bleeding were observed on brain MRI analysis, and no bleeding‐related responses were found on laboratory testing. The plasma levels of the coagulation factor fibrinogen and the anti‐fibrinolysis factor α 2 ‐antiplasmin levels were unchanged after TMS‐007 dosing. A slight increase in the plasma level of plasmin‐α 2 ‐antiplasmin complex, an index of plasmin formation, was observed in the TMS‐007 group in cohort 2.
Conclusions
TMS‐007 is generally well tolerated and exhibits favourable pharmacokinetic profiles that warrant further clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research Support Center, University of Tokyo Hospital, Tokyo, Japan.
- Division of Research and Development, TMS Co., Ltd., Tokyo, Japan.
- Department of Geriatric Medicine, University of Tokyo Hospital, Tokyo, Japan.
- Department of Neuropsychiatry, University of Tokyo Hospital, Tokyo, Japan.
- Disability Services Office, University of Tokyo, Tokyo, Japan.
- Precision Health, Department of Bioengineering, Graduate School of Engineering, University of Tokyo, Tokyo, Japan.
ORCID-Profile: Keiji Hasumi
Förderung
- Japan Science and Technology Agency
Zitieren
APA
Moritoyo, T., Nishimura, N., Hasegawa, K., Ishii, S., Kirihara, K., Takata, M., Svensson, A. K., Umeda-Kameyama, Y., Kawarasaki, S., Ihara, R., Sakanaka, C., Wakabayashi, Y., Niizuma, K., Tominaga, T., Yamazaki, T., & Hasumi, K. (2023). A first‐in‐human study of the anti‐inflammatory profibrinolytic TMS‐007, an SMTP family triprenyl phenol. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15651
Vancouver
Moritoyo T, Nishimura N, Hasegawa K, Ishii S, Kirihara K, Takata M, et al. A first‐in‐human study of the anti‐inflammatory profibrinolytic TMS‐007, an SMTP family triprenyl phenol. British Journal of Clinical Pharmacology. 2023. doi:10.1111/bcp.15651
BibTeX
@article{Moritoyo2023,
author = {Moritoyo, Takashi and Nishimura, Naoko and Hasegawa, Keiko and Ishii, Shinya and Kirihara, Kenji and Takata, Munenori and Svensson, Akiko Kishi and Umeda-Kameyama, Yumi and Kawarasaki, Shuichi and Ihara, Ryoko and Sakanaka, Chie and Wakabayashi, Yurie and Niizuma, Kuniyasu and Tominaga, Teiji and Yamazaki, Tsutomu and Hasumi, Keiji},
title = {A first‐in‐human study of the anti‐inflammatory profibrinolytic TMS‐007, an SMTP family triprenyl phenol},
journal = {British Journal of Clinical Pharmacology},
year = {2023},
doi = {10.1111/bcp.15651}
}
EUVIMED